Vaudreuil-Dorion, Quebec, Oct. 22, 2024 (GLOBE NEWSWIRE) — Hangcha Forklift Canada (“Hangcha Canada” or “the Company”), a wholly-owned subsidiary of the esteemed Hangcha Group has officially marked five years since its establishment on October 18, 2019. Launched with an initial investment of USD 3 million, Hangcha Canada entered the market aiming to bypass importers and […]

San Diego, CA, Oct. 22, 2024 (GLOBE NEWSWIRE) — Truepic, the enterprise solution for digital content authenticity, and Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, announced that Truepic has been recognized as one of Inc.’s Power Partner Best B2B Providers in the Business Products and Services

BOTHELL, Wash., Oct. 22, 2024 (GLOBE NEWSWIRE) — Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD) will be presented at the 17th Annual

WALTHAM, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2024 financial results on Tuesday, November 5, 2024, at 8:30 a.m. ET. To access the live call by phone, please pre-register for the call here.

SAN FRANCISCO, Oct. 22, 2024 (GLOBE NEWSWIRE) — WHO: Tenor, providers of AI-driven leadership development solutions that redefine traditional training WHAT: Will present “Leadership Skills in the Age of AI” during the Association for Talent Development (ATD) Leadership Development Day. WHEN: Wednesday, October 30, 2024, from 10:00 a.m. to 4:00 p.m. ET. Tenor’s session will

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is

London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, announces upcoming oral and poster presentations at the 2024 European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, held in Rome, Italy (October 22-25,

Nodenza Venture Partners invests in Trellis Bioscience Lead product TRL1068 targets biofilm, estimated to cause 60-70% of antibiotic resistant infections New York, October 22, 2024 – Nodenza Venture Partners (“Nodenza”), today announces its investment in Trellis Bioscience (“Trellis”), a clinical-stage company focused on discovering and developing native human monoclonal antibodies to treat and prevent drug-resistant,

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is

Acquisition brings premium LED lighting solutions into Garmin’s product portfolio Garmin Ltd. (NYSE: GRMN) today announced it has acquired Lumishore, a privately-held company that designs and manufactures high-performance above and underwater LED lighting systems for boats. https://mma.prnewswire.com/media/2536247/Garmin_Lumishore.jpg “Lumishore brings an exciting new product category that complements Garmin’s existing marine portfolio and furthers our ability to